Send this to a friend

Medical diagnostics technology company T2 Biosystems Inc. has won a patent that broadly covers using nuclear magnetic resonance to detect analytes.

In a release issued today, Lexington-based T2 Biosystems said that the U.S. Patent and Trademark Office issued the patent number 8,102,176 titled “NMR Device for Detection of Analytes.”

The company’s T2MR diagnostic technology is currently going through clinical trials for an assay intended to detect Candida, a fungal pathogen linked to bloodstream infections, in less than two hours, rather than the typical one or more days that also requires sample purification and blood culture growth. T2 Biosystems has said that it expects to submit it for FDA approval in the second half of 2012.

In today’s release, T2 Biosystems noted that its T2MR platform can be used to detect “any immunologic, hemostasis, or molecular target.”

T2 Biosystems reported in May that it had secured an Emerging Technology Loan, valued at about $1.7 million, from MassDevelopment, a finance and development agency for Massachusetts businesses and organizations.

Related links:

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.